The Immutep Ltd (ASX: IMM) share price is currently halted on Monday. This comes after the biotech company requested a trading halt from the ASX late last week.
Before being placed on ice, shares in the cancer immunotherapy developer finished Friday’s session up 3.95% to 39.5 cents.
Despite that gain, the stock has had a softer start to the year and remains around 5% lower in 2026.
Let’s take a look at what is happening with this ASX healthcare share.
Trading halt ahead of important clinical update
According to the release, Immutep requested that its shares be paused while it prepares to release a significant update to the market.
The pause relates to an upcoming update on the company’s Phase III TACTI 004 clinical trial.
Management said the move is designed to ensure trading does not occur on an uninformed basis while the company prepares its announcement.
Immutep stated that the trading halt will remain in place until the earlier of an announcement being released or the commencement of trading on 11 March 2026.
Investors are now waiting for the company to disclose the results of the interim analysis.
What the clinical trial is testing
Immutep is an Australian biotechnology company developing new treatments that help the immune system fight cancer and other diseases.
Its lead drug candidate is called eftilagimod alpha. The treatment works by stimulating the body’s immune system so it can better recognise and attack cancer cells.
The company is currently running a late-stage Phase III clinical trial known as TACTI 004, also called the KEYNOTE F91 study.
This trial is testing eftilagimod alpha alongside Keytruda, a widely used cancer treatment developed by pharmaceutical giant Merck.
The study focuses on patients with advanced head and neck cancer that has either returned or spread to other parts of the body.
As part of the trial, researchers are carrying out what is known as a futility analysis. This is an interim check to see whether the treatment appears likely to deliver positive results.
If the early data suggest the trial is on the right track, the study will continue. If not, researchers may decide it is unlikely to meet its goals.
Because this is a Phase III study, it is one of the final stages of clinical testing. The outcome of this analysis could have a major impact on Immutep’s future.
What investors will be watching
Biotech shares often react strongly to clinical trial updates, particularly when they involve late-stage studies.
If the futility analysis indicates the trial should continue, it could strengthen investor confidence in Immutep’s development pipeline.
However, if the results are disappointing, the market could react negatively.
The post Why the Immutep share price is halted today appeared first on The Motley Fool Australia.
Should you invest $1,000 in Immutep Limited right now?
Before you buy Immutep Limited shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Immutep Limited wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 20 Feb 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- Why Catapult Sports, CBA, Dyno Nobel, and Qantas shares are sinking today
- US$100 oil is a big deal for every ASX share. Here’s why
- Why Amplitude Energy, Cogstate, Dexus Convenience Retail, and Santos shares are charging higher
- Here’s why Woodside shares are demolishing the stock market
- Leading brokers name 3 ASX shares to buy today
Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.